期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

抗Trastuzumab单克隆抗体制备及其双抗体夹心ELISA检测方法的建立

原文传递
导出
摘要 本研究利用曲妥珠单抗（Trastuzumab）4次腹腔免疫 6-8 周龄BALB/c 雌性小鼠.通过淋巴细胞杂交瘤技术、间接ELISA 筛选技术及腹水制备等技术制备并获得抗Trastuzumab单克隆抗体.试验结果表明,通过细胞融合获得了一株能稳定分泌抗Trastuzumab的杂交瘤细胞株A6E8,其制备的腹水单克隆抗体纯化后效价为256000,该抗体属于IgG1亚类,链的类型为k链.利用制备的单克隆抗体（McAb）建立Trastuzumab双抗体夹心ELISA检测方法,试验结果显示,该检测方法特异性良好,不与其他抗体及蛋白发生交叉反应,所建立的Trastuzumab双抗体夹心ELISA 方法最低检测限为1ng/mL.
作者 王延涛 赵喜红 王锐
机构地区 黑龙江哈尔滨哈药集团生物工程有限公司 黑龙江哈尔滨哈药集团技术中心
出处 《按摩与康复医学》 2011年第17期55-55,共1页 Chinese Manipulation and Rehabilitation Medicine
关键词 TRASTUZUMAB 单克隆抗体 双抗体夹心ELISA 药物代谢动力学
分类号 R4 [医药卫生—临床医学]
  • 相关文献

参考文献2

二级参考文献15

  • 1Sliwkowshi MX, Lofgren JA, Lewis GD, et al. Nonclinical studies addressing the mechanism of action of Trastuzumab (Herceptin)[J]. Semin Oncol, 1999, 26(4 Suppl 12): 60-70.
  • 2Pietras RJ, Poen JC, Gallardo D, et al. Monoclonal antibody to HER-2/neu receptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene[ J]. Cancer Res, 1999, 59: 1347- 1355.
  • 3Celmon K, Arnold A, Verma S, et al. Pharmacokinetics (PK) and safety of Herceptin (R) when administered every three weeks to women with metastatic breast cancer[ J]. Proc Am Soc Clin Oncol, 2001,20: 69a.
  • 4Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER-2 monoclonal antibody in women who have HER-2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease [J]. J Clin Oncol, 1999, 17: 2639-2648.
  • 5Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER-2-overexpressing metastatic breast cancer[ J]. J Clin Oncol, 2002, 20(3): 719-726.
  • 6Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER-2 for metastatic breast cancer that overexpresses HER-2[J]. N Engl J Med, 2001, 344(11): 783-792.
  • 7Fyfe GA, Mass R, Murphy M, et al. Survival benefit of trastuzumab (Herceptin) and chemotherapy in older ( ＞ 60) patients [ J ].Proc Am Soc Clin Oncol, 2001, 20: 48a.
  • 8Seidman AD, Fornier MN, Esteva FJ, et al. Weekly trastuzumab and paclitaxel therapy for metasiatic breast cancer with analysis of efficacy by HER-2 immunophenotype and gene amplification[ J]. J Clin Oncol, 2001, 19(10): 2587-2595.
  • 9Esteva FJ, Valero V, Booser D, et al. Phase Ⅱ study of weekly docetaxel and trastuzumab for patients with HER-2-overwxpressing metastatic breast cancer[J]. J Clin Oncol, 2002, 20(7): 1800-1808.
  • 10Uber KA, Nicholson BP, Thor AD, et al. A phase Ⅱ trial of weekly docetaxel (D) and Herceptin ( H ) as first-or second-line treatment in HER-2 over-expressing metastatic breast cancer [ J ].Proc Am Soc Clin Oncol, 2001,20: 50b.

共引文献7

按摩与康复医学
2011年 第17期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部